Incyte posts Phase 3 STOP-HS2 results for povorcitinib; registers INCB161734 Phase 1 study

Incyte's week included newly posted Phase 3 results in hidradenitis suppurativa and a completed early-stage pharmacokinetics study of an investigational compound.

• Povorcitinib (INCB054707), an oral tablet, was tested in a Phase 3 trial called "STOP-HS2" (NCT05620836) for participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.¹ The study started on 2023-02-22, reached primary completion on 2025-01-07, and completed on 2025-11-21, with results first posted on 2026-11-05.¹ It enrolled 619 participants¹ and its primary outcome was the Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12, defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count.¹
• A Phase 1 study of INCB161734 (NCT07814404), titled "A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants," was reported as completed. The study started on 2026-09-18, reached primary completion on 2026-10-15, and completed on 2026-10-15, with first posting on 2026-09-11.² It enrolled 10 participants² and examined total recovery of administered radioactivity in urine and feces, reported as the percentage of the administered radioactivity excreted.²